<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37192138</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-0960</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Australasian journal of dermatology</Title><ISOAbbreviation>Australas J Dermatol</ISOAbbreviation></Journal><ArticleTitle>Successful treatment of classic pyoderma gangrenosum with intralesional infliximab injection: A case report.</ArticleTitle><Pagination><StartPage>e252</StartPage><EndPage>e255</EndPage><MedlinePgn>e252-e255</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ajd.14072</ELocationID><Abstract><AbstractText>Pyoderma gangrenosum (PG) is a rare dermatological disease characterized by the rapid development of painful skin ulcers. While systemic infliximab is considered a standard treatment for patients with PG, herein, we report our success with the use of intralesional infliximab in a 40-year-old woman with systemic lupus erythematosus (SLE) and PG.</AbstractText><CopyrightInformation>&#xa9; 2023 Australasian College of Dermatologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Kourosh</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8869-266X</Identifier><AffiliationInfo><Affiliation>Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aflaki</LastName><ForeName>Elham</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1191-1494</Identifier><AffiliationInfo><Affiliation>Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbarzade Jahromi</LastName><ForeName>Mojgan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0874-3127</Identifier><AffiliationInfo><Affiliation>Pathology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dastgheib</LastName><ForeName>Ladan</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2117-9375</Identifier><AffiliationInfo><Affiliation>Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Australas J Dermatol</MedlineTA><NlmUniqueID>0135232</NlmUniqueID><ISSNLinking>0004-8380</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017511" MajorTopicYN="Y">Pyoderma Gangrenosum</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Remicade</Keyword><Keyword MajorTopicYN="N">drug therapy</Keyword><Keyword MajorTopicYN="N">intralesional injection</Keyword><Keyword MajorTopicYN="N">pyoderma gangrenosum</Keyword><Keyword MajorTopicYN="N">tumour necrosis factor-&#x3b1; inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>19</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>13</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37192138</ArticleId><ArticleId IdType="doi">10.1111/ajd.14072</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Maverakis E, Marzano AV, Le ST, Callen JP, Br&#xfc;ggen M-C, Guenova E, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):1-19. https://doi.org/10.1038/s41572-020-0213</Citation></Reference><Reference><Citation>Xu A, Balgobind A, Strunk A, Garg A, Alloo A. Prevalence estimates for pyoderma gangrenosum in the United States: an age-and sex-adjusted population analysis. J Am Acad Dermatol. 2020;83(2):425-9. https://doi.org/10.1016/j.jaad.2019.08.001</Citation></Reference><Reference><Citation>Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges. 2017;15(1):34-40. https://doi.org/10.1111/ddg.13173</Citation></Reference><Reference><Citation>Partridge ACR, Bai JW, Rosen CF, Walsh SR, Gulliver WP, Fleming P. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. Br J Dermatol. 2018;179(2):290-5. https://doi.org/10.1111/bjd.16485</Citation></Reference><Reference><Citation>Su WD, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790-800. https://doi.org/10.1111/j.1365-4632.2004.02128</Citation></Reference><Reference><Citation>Seivright JR, Villa NM, De DR, Hsiao JL, Shi VY. Intralesional biologics for inflammatory dermatoses: a systematic review. Dermatol Ther. 2022;35(2):e15234. https://doi.org/10.1111/dth.15234</Citation></Reference><Reference><Citation>Wallace HJ, Stacey MC. Levels of tumor necrosis factor-&#x3b1; (TNF-&#x3b1;) and soluble TNF receptors in chronic venous leg ulcers-correlations to healing status. Journal of Investigative Dermatology. 1998;110(3):292-6. https://doi.org/10.1046/j.1523-1747.1998.00113</Citation></Reference><Reference><Citation>Streit M, Beleznay Z, Braathen LR. Topical application of the tumour necrosis factor-&#x3b1; antibody infliximab improves healing of chronic wounds. Int Wound J. 2006;3(3):171-9. https://doi.org/10.1111/j.1742-481X.2006.00233</Citation></Reference><Reference><Citation>Teich N. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease. Tech Coloproctol. 2014;18(10):965-6. https://doi.org/10.1007/s10151-014-1192-2</Citation></Reference><Reference><Citation>Teich N, Klugmann T. Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis. 2014;8(1):85-6. https://doi.org/10.1016/j.crohns.2013.06.003</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>